ARTICLE | Management Tracks
Lin leaving Nektar as CMO; plus HKEX’s Tai named interim CEO, PureTech, Patient Square Capital, Novacyt and more
January 6, 2021 2:39 AM UTC
Wei Lin is leaving Nektar Therapeutics (NASDAQ:NKTR) as CMO to pursue another opportunity. Brian Kotzin, who is SVP, clinical development and head of immunology at the company, will serve as interim CMO, head of development.
Hong Kong Exchanges and Clearing Ltd. named co-President and COO Chi Kin Tai interim CEO while it searches for a successor to Charles Li, who retired. Tai has been with HKEX, which operates the Stock Exchange of Hong Kong, for the past 22 years. Li will advise HKEX for six months...